Koichiro Yoneyama

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 6

Top Topics

Atrial Fibrillation

Prognostic Factors

Top Venues

Thrombosis and haemostasis

Expert review of clinical pharmacology

Journal of clinical pharmacology

This page only lists publications with an associated author ORCID identifier.

Publications

Midori Shima, Nobuaki Suzuki, Hidekazu Nishikii, Kagehiro Amano, Yoshiyuki Ogawa, Ryota Kobayashi, Ryoto Ozaki, Koichiro Yoneyama, Narumi Mizuno, Emiko Sakaida, Makoto Saito, Takashi Okamura, Toshihiro Ito, Norimichi Hattori, Satoshi Higasa, Yoshinobu Seki, Keiji Nogami
Final Analysis Results from the AGEHA Study: Emicizumab Prophylaxis for Acquired Hemophilia A with or without Immunosuppressive Therapy. Thrombosis and haemostasis (2024)
Koichiro Yoneyama, Christophe Schmitt, Agnès Portron, Anna Kiialainen, Naoki Kotani, Felix Jaminion, Sylvie Retout, Joanne I Adamkewicz
Clinical pharmacology of emicizumab for the treatment of hemophilia A. Expert review of clinical pharmacology (2023)
Koichiro Yoneyama, Christophe Schmitt, Tiffany Chang, Christophe Dhalluin, Sayaka Nagami, Claire Petry, Gallia G Levy
A Model-Based Framework to Inform the Dose Selection and Study Design of Emicizumab for Pediatric Patients With Hemophilia A. Journal of clinical pharmacology (2021)
Midori Shima, Keiji Nogami, Sayaka Nagami, Seitaro Yoshida, Koichiro Yoneyama, Akira Ishiguro, Takashi Suzuki, Masashi Taki
A multicentre, open-label study of emicizumab given every 2 or 4 weeks in children with severe haemophilia A without inhibitors. Haemophilia : the official journal of the World Federation of Hemophilia 25 (6) (2019)
Koichiro Yoneyama, Christophe Schmitt, Naoki Kotani, Gallia G Levy, Ryu Kasai, Satofumi Iida, Midori Shima, Takehiko Kawanishi
A Pharmacometric Approach to Substitute for a Conventional Dose-Finding Study in Rare Diseases: Example of Phase III Dose Selection for Emicizumab in Hemophilia A. Clinical pharmacokinetics 57 (9) (2019)
Midori Shima, Hideji Hanabusa, Masashi Taki, Tadashi Matsushita, Tetsuji Sato, Katsuyuki Fukutake, Ryu Kasai, Koichiro Yoneyama, Hiroki Yoshida, Keiji Nogami
Long-term safety and efficacy of emicizumab in a phase 1/2 study in patients with hemophilia A with or without inhibitors. Blood advances 1 (22) (2017)